How much does Rozebalamin (methylcobalamin), a Japanese original drug, cost?

Rozebalamin(Methylcobalamin) is a drug produced by Japan's Eisai Co., Ltd. (Eisai) and is used to treat amyotrophic lateral sclerosis (ALS). As a drug to treat ALS, it has not yet been officially launched in China, so it can only be purchased through overseas channels. The price of Japanese original drugs is usually higher because it is an innovative drug that has been developed and clinically proven, and imported drugs often involve additional costs.

According to the current market conditions, the price of Japan's original drug Rozebalamin is about 7,000 RMB per box. Each box contains 8 bottles, each bottle has a specification of 25mg. According to the recommended dosage, approximately 16 bottles are needed per month, so the monthly treatment cost is approximately 14,000 RMB. This price is mainly for the Japanese market. Cross-border purchases may also involve additional charges such as freight and customs duties, resulting in higher overall costs.

Patients who purchaseRozebalamin usually need to obtain it through purchasing agents, international drug e-commerce platforms or other overseas channels. Since the supply of this drug exceeds demand in the Japanese market and there may be price fluctuations, patients need to conduct sufficient research before purchasing and ensure the formality and safety of the purchasing channels. Prices may vary by channel, and patients should confirm final pricing and shipping conditions with their trusted supplier.

Despite its higher price, Rozebalamin is still considered to have important clinical value as an effective treatment option for patients in need of treatment for ALS. When deciding whether to purchase, patients should consider the efficacy, treatment cycle and personal financial situation. It is recommended that treatment decisions be made under the guidance of a professional doctor.

xa0

References:

[1]https://pins.japic.or.jp/pdf/newPINS/00071540.pdf

[2]https://www.eisai.com/news/2024/news202487.html